BACKGROUND OF THE INVENTION Calcium channels convert electrical signals in the cell membrane into an increase in intracellular calcium, thereby activating many crucial physiological processes, including muscle contraction, hormone secretion, neurotransmission, synaptic plasticity, regulation of enzymatic activites and gene expression. Calcium channels can be classified into a number of types and subtypes, for example L- (or Caul), P/Q- (or Cav2. 1), N- (or Cav2. 2), R- (Cav2. 3) and T- (or Cay3) types. T-type calcium channels can, for example, be subclassified into oclG (or Cav3.1), alH (or Cav3. 2), and all (or Cav 3.3) T channels. See, e. g. , Catterall et al. , Annu. Rev. Cell Dev. Biol. 16,521-55, (2000); and Perez-Reyes et al. , Physiol. Rev. 83,117-161, (2003).

Physiologically, calcium channels are distributed widely. For example, T-type channels can be found in neurons, the heart, kidney, smooth muscle, skeletal muscle, sperm, and endocrine tissues (such as adrenal and pituitary glands and the pancreas).

Consequently, T-type calcium channels are thought to be involved in autonomic nervous functions, and in regulation of cardiovascular activities such as heart rate, arterial and venous smooth muscle innervation and tone, pulmonary rate, and other critical processes.

Due to their role in modulating many physiological processes, abnormal or unwanted calcium channel activity is also associated with many disease states.

Agents which antagonize or agonize the activity of calcium channels have been

shown to be useful as therapies for treating a wide variety of diseases and disorders.

See, e. g., WO 99/23072; EP 0545845; and Kochegarov et al., Expert Opin. Ther.

Patents, 12, 243-287, (2002).

L-channel blockers have a well established role in the treatment of diseases such as hypertension and angina (see e. g. Mannhold et al., Drugs of Today, 30,103- 122,1994). Compounds that have exclusively or predominantly T-channel blocking activity or that have dual L-and T-channel blocking activities are considered to be useful for the treatment of hypertension, angina, arrhythmia, congestive heart failure, renal disease, epilepsy, neuropathic pain, and other diseases and conditions. See, e. g., Perez-Reyes et al., Physiol. Rev. 83,117-161 (2003) and WO 03/07953.

T-channel blockers are also useful for the treatment of sleep disorders, mood disorders, depression, migrane headache, neuronal excitability disorders, hyperaldosteronemia, preterm labor, urinary incontinence, brain aging, or neurodegenerative related diseases such as Alzheimer's disease. See, e. g. , WO 01/02561 ; WO 00/02455; JP11035483 and Chemin et al. , J. Physio., 540,3-14, (2002). Additionally, T-type calcium channels play a role in pancreatic beta-cell insulin secretion. Therefore, T-type blockers may be useful for treatment of hypo- and hyperinsulinemia and the treatment and/or prevention of type 1 and type 2 diabetes as well as microvascular or macrovascular diseases associated with diabetes.

See, e. g. , Bhattacharjee et al., Endocrinology, 138,3735-40, (1997) and WO 00/15845. T-type calcium channel blockers may also be useful in the treatment of cancer. See, e. g. , WO 00/59882 and WO 01/019845.

Drugs such as mibefradil and efonidipine which block both T and L calcium channels have been shown to be useful or potentially useful in a variety of disease states. Such drugs may have therapeutic advantages over calcium channel blockers that predominantly target the L-channel. For example, mibefradil was shown to be useful for the treatment of hypertension and angina and did not show the negative side-effects including inotropy, reflex tachycardia, vasoconstrictive hormone release or peripherial edema, which are often shown by predominantly L-channel blockers.

See, e. g., Sandman et al. , J. Clin. Basic Cardiol., 2, 187-201 (1999) and Glasser et al., J. Clin. Pharmacol., 38,659-669 (1998). Also, mibefradil has been shown to be potentially cardioprotective (see e. g. Villame, Cardiovascular Drugs and Therapy, 15,

41-48 (2001) and Ramies, et al. , J. Mol. Cell Cardiol., 30,475-483, (1998)) and renal protective (see e. g. Honda, J. et al., Hypertension, 19,2031-2037 (2001); Baylis et al., Am. J. Kidney Dis., 38, 1292-1297 (2001) ; Qiu, et al. , J. Hypertension, 1489-1495 (1999); and Karam et al., Hypertension, 34,673-678, (1999) ). Also, unlike most predominant L-channel blockers, mibefradil has been shown to be potentially useful in the treatment of heart failure. See, e. g. , Clozel, et al., Proceedings of the Association of American Physicians, 111, 429-437 (1999); Mulder, et al., Journal of the American College of Cardiology, 29,416 (1997); and Meissner, et al., Exp. Biol.

Med 227, 336-44, (2002). Mibefradil may also be useful in the treatment of atherosclerosis (see e. g. Mason, et al., Biochemical Pharmacology, 55, 1843-1852, (1998) ) and inflammation (see, e. g. , Bilici, et al., Pharmacological Research, 527-531 (2001)). Efonidipine, another calcium channel blocker with a combination of T-and L-channel blocking activities, also shows therapeutic advantages over pure L-channel blockers. See, e. g. , Harada, et al. , Circ. J. 67,139-145 (2003); Hayashi, et al., Amer.

Heart J., 16,116-122 (2003); and Tanaka, et al., Cardiovascular Drug Reviews, 20, 81-92 (2002).

SUMMARY OF THE INVENTION The present invention provides dihydropyrimidone compounds, pharmaceutical compositions containing such dihydropyrimidone compounds, and methods for treating calcium channel-dependent disorders using such compounds and compositions. Specifically, the invention provides compounds of Formula I: enantiomers, diastereomers, solvates and salts thereof, wherein A is aryl or heteroaryl, each of which may be optionally substituted with Z1, Z2 and/or one or more Z3 ;

X is oxygen or sulfur; J is alkylene, alkenylene, or alkynylene any of which may be optionally substituted with Zla, Z2a and/or one or more Z3a ; R1 is hydrogen, alkyl, alkenyl or alkynyl any of which may be optionally substituted with Zlb, Z2b and/or one or more Z3b Ris (a) alkyl, alkoxy or aryloxy, each group optionally substituted with Z1c, Z2c and/or one or more Z3c; (b) cyano or nitro; or (c) -C (O) R5 or C(O)OR5 ; R3 is (a)-N(R6) C (O) R7, -N(R6) C (O) oR7,-N (R6) C (O)-NR7R8, -OC(O) NR6R7,- NR6S (O) tR7,-S (O) tNR6R7 or S (O) tR6 where t is 1 or 2; or (b) a group of formula (c) a group of formula R4 is (a) hydrogen; or (b) alkyl, cycloalkyl, aryl, heterocyclo, heteroaryl, (aryl) alkyl, (cycloalkyl) alkyl, (heterocyclo) alkyl or (heteroaryl) alkyl, any of which may be optionally substituted with zle, Z2e and/or one or more z3e ; RS is (a) hydrogen; or

(b) alkyl, cycloalkyl, aryl, heterocyclo, heteroaryl, (aryl) alkyl, (cycloalkyl) alkyl, (heterocyclo) alkyl or (heteroaryl) alkyl, any of which may be optionally substituted with Z1f, Z2f and/or one or more R6, R7 and R8 are independently (a) hydrogen; (b) alkyl, cycloalkyl, aryl, heterocyclo, heteroaryl, (aryl) alkyl, (cycloalkyl) alkyl, (heterocyclo) alkyl or (heteroaryl) alkyl, any of which may be optionally substituted with Zlg, Z2g and one or more Z3g ; or (c) R6 and R7 are optionally taken together to form (i) an alkylene or alkenylene group; (ii)-N=CR9-; (iii)-N=N-; or R9 is (a) hydrogen; or (b) alkyl, cycloalkyl, aryl, heterocyclo, heteroaryl, (aryl) alkyl, (cycloalkyl) alkyl, (heterocyclo) alkyl or (heteroaryl) alkyl, any of which may be optionally substituted with Z1g, Z2g and/or one or more Z3g ; Z1-1g, Z2-2g, and Z3-3g are optional substituents independently selected from (1) R10, where Rlo is (i) alkyl, (hydroxy) alkyl, (alkoxy) alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl) alkyl, cycloalkenyl, (cycloalkenyl) alkyl, aryl, (aryl) alkyl, heterocyclo, (heterocylco) alkyl, heteroaryl, or (heteroaryl) alkyl; (ii) a group (i) which is itself substituted by one or more of the same or different groups (i); or (iii) a group (i) or (ii) which is independently substituted by one or more (preferably 1 to 3) of the following groups (2) to (13) of the definition of Zl, <BR> <BR> <BR> (2)-OH or-OR", <BR> <BR> <BR> <BR> <BR> <BR> (3)-SH or-SRIO, (4)-C (O) tH,-C (O) tR10, or -O-C(O)R10, where t is 1 or 2, (5)-S03H,-S (O) tR, or S (O) tN (R11) R,

(6) halo, (7) cyano, (8) nitro, (9) -U1-NR12R13, (10)-Ul-N (Rll)-U2-N R R13 (11) -U1-N(R14)-U2-R10, (12) -U1-N(R14)-U2-H, (13) oxo; Ul and u2 are each independently (1) a single bond, (2) -U3-S(O)t-U4-, (3) -U3-C(O)-U4-, (4) -U3-C(S)-U4-, (5) -U3-O-U4-, (6) -U3-S-U4-, (7) -U3-O-C(O)-U4-, (8) -U3-C(O)-O-U4-, (9) -U3-C (=NR15)-U4-, or (10) -U3-C(O)-C(O)-U4-; R11, R12, R13, R14 and R15 (1) are each independently hydrogen or a group provided in the definition of zl ; or (2) R12 and R13 may together be alkylene or alkenylene, completing a 3-to 8- membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the definition of Zl, or (3) R12 or R13, together with R11, may be alkylene or alkenylene completing a 3-to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the definition of Zl, or

(4) R12 and R13 together with the nitrogen atom to which they are attached may combine to form a group-N=C R16 R17 where R16 and R 17 are each independently H or a group provided in the definition of Rlo ; and U3 and U4 are each independently (1) a single bond, (2) alkylene, (3) alkenylene, (4) alkynylene.

This invention is also directed to pharmaceutical compositions comprising at least one compound of formula (I) and a pharmaceutically acceptable vehicle, carrier or diluent.

This invention is also directed to methods of treating a mammalian host to relieve one or more calcium channel-dependent disorders comprising administering to said host in need of such treatment an effective amount a pharmaceutical composition comprising a compound of formula (I).

Detailed Description of the Invention The following are definitions of terms used in this specification. The initial definition provided for a group or term herein applies to that group or term throughout the present specification, individually or as part of another group, unless otherwise indicated.

The term"alkyl"as used herein by itself or as part of another group refers to straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4, 4-dimethylpentyl, octyl, 2,2, 4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are often most preferred.

The term"alkenyl"as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-

pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3- octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8, 12-tetradecatrienyl, and the like.

The term"alkynyl"as used herein by itself or as part of another group refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms, preferably 2 to 4 carbon atoms, and at least one triple carbon to carbon bond, such as ethynyl, 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3- hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3- undecynyl, 4-dodecynyl and the like.

Where alkyl groups as defined above have single bonds for attachment to two other groups, they are termed"alkylene"groups. Similarly, where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment to two other groups, they are termed"alkenylene groups"and "alkynylene groups"respectively. Examples of alkylene, alkenylene and alkynylene groups include:

The term"cycloalkyl"as used herein by itself or as part of another group refers to saturated and partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 7 carbons, forming the ring. The rings of multi-ring cycloalkyls may be either fused, bridged and/or joined through one or more spiro union to 1 or 2 aromatic, cycloalkyl or heterocyclo rings. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, cycloheptadienyl,

0 \ Y w a N I\ / The term"cycloalkylene"as employed herein refers to a"cycloalkyl"group which includes free bonds and thus is a linking group such as V L. J and the like.

The terms"ar"or"aryl"as used herein by itself or as part of another group refer to aromatic homocyclic (i. e. , hydrocarbon) monocyclic, bicyclic or tricyclic aromatic groups containing 6 to 14 carbons in the ring portion (such as phenyl, biphenyl, naphthyl (including 1-naphthyl and 2-naphthyl) and antracenyl) and may optionally include one to three additional rings (either cycloalkyl, heterocyclo or heteroaryl) fused thereto. Examples include:

and the like.

The terms"halogen"and"halo"as used herein by itself or as part of another group refer to fluorine, chlorine, bromine and iodine. Haloalkyl refers to an alkyl chain substituted with from one to three halogens.

The term"heteroaryl"as used herein by itself or as part of another group refers to monocyclic and bicyclic aromatic rings containing from 5 to 10 atoms, which includes 1 to 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or heterocyclo ring, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. Examples of heteroaryl groups include the following: and the like.

The terms"heterocyclic"or"heterocyclo"as used herein by itself or as part of another group refer to optionally substituted, fully saturated or partially unsaturated cyclic groups (for example, 3 to 13 member monocyclic, 7 to 17 member bicyclic, or 10 to 20 member tricyclic ring systems, preferably containing a total of 3 to 10 ring atoms) which have at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2,3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. The heterocyclic group may be attached

at any heteroatom or carbon atom of the ring or ring system, where valance allows.

The rings of multi-ring heterocycles may be either fused, bridged and/or joined through one or more spiro unions. Exemplary heterocyclic groups include azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-l, l-dioxothienyl,

te0 r--"*,- I N O 0 o/o/N , . and the like.

The term"ring"encompasses homocyclic (i. e. , as used herein, all the ring atoms are carbon) or"heterocyclic" (i. e. , as used herein, the ring atoms include carbon and one to four heteroatoms selected from N, O and/or S, also referred to as heterocyclo), where, as used herein, each of which (homocyclic or heterocyclic) may be saturated or partially or completely unsaturated (such as heteroaryl).

Throughout the specification, groups and substituents thereof may be chosen to provide stable moieties and compounds.

The compounds of formula I form salts which are also within the scope of this invention. Reference to a compound of the formula I herein is understood to include reference to salts thereof, unless otherwise indicated. The term"salt (s) ", as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, when a compound of formula I contains both a basic moiety and an acidic moiety, zwitterions ("inner salts") may be formed and are included within the term"salt (s)" as used herein. Pharmaceutically acceptable (i. e. , non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, e. g. , in isolation or purification steps which may be employed during preparation.

Salts of the compounds of the formula I may be formed, for example, by reacting a compound I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

The compounds of formula I which contain a basic moiety may form salts with a variety of organic and inorganic acids. Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates,

benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.

The compounds of formula I which contain an acidic moiety may form salts with a variety of organic and inorganic bases. Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines (formed with N, N-bis (dehydroabietyl) ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e. g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e. g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e. g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e. g. benzyl and phenethyl bromides), and others.

Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term"prodrug", as employed herein, denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of the formula I, or a salt and/or solvate thereof. Solvates of the compounds of formula I are preferably hydrates. Any tautomers which may exist are also contemplated herein as part of the present invention. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:

a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymologv. Vol. 42, p. 309-396, edited by K. Widder, et al. (Acamedic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krosgaard- Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs,"by H.

Bundgaard, pp. 113-191 (1991) ; and c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992), each of which is incorporated herein by reference.

All stereoisomers of the present compounds, such as those which may exist due to asymmetric carbons on the R substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons, e. g. , atropisomers) and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.

Methods of Preparation The compounds of the present invention may be prepared by methods such as those illustrated in the following Schemes 1 through 6. Solvents, temperatures, pressures, and other reaction conditions may be selected by one of ordinary skill in the art. Starting materials are commercially available or readily prepared by one of ordinary skill in the art.

Scheme 1 describes the preparation of the pyrimidine core intermediates. See J. Med. Chem. 33 (5), 1510, (1990). Briefly, an aryl (as depicted in schemes 1-6) or heteroaryl aldehyde 1 is condensed with ketone 2 in the presence of a base such as pyridine to afford a-benzylidine intermediate 3, which is reacted with O- methylisourea or S-methylisothiourea to afford the core structure 4.

Scheme 1

In scheme 2, the pyrimidine core intermediate 4 is alkylated in the presence of a base, such as sodium hydide with a side-chain intermediate 5 to provide intermediate 6. L is a leaving group such as bromo, iodo, or tosyl, and P is an amino protecting group such as Boc or Cbz. Acids such as TFA or HC1 are employed to remove acid-labile protecting groups P (such as Boc groups) and, at the same time, hydrolyze the methoxy or methylthio group to afford intermediate 7. Condensation of the side-chain amine of 7 with an acid chloride in the presence of base such a triethylamine or with an acid in the presence of DCC affords the compound of invention la.

When protecting groups, "P", of intermediate 6 are removed under non-acidic conditions the 2-methyoxy or 2-methylthio group may remain intact and require a separate hydrolysis step for its removal. For example, if P is CBZ and X is oxygen, hydrogenolysis removes the CBZ group to afford 8 and the 2-methyoxy group is hydrolyzed in a separate step using, for example, TFA or aqueous HC1 to afford 7.

Scheme 2

L I 2 p \-z3 deprotection N R 6 H 6 7 zl ci-CO-R' or H02C-R > Ruz NJNCO-R 1 Nix H la As illustrated in scheme 3, treatment of intermediate 7 with a a) sulfonyl chloride, b) chloroformate, c) N, N-dialkylcarbamoylchloride, or d) isocyanate provides compounds of the invention Ib, Ic, Id, and Ie, respectively.

Scheme 3

As described in scheme 4, alkylation of core intermediate 4 with protected acid 10 provides intermediate 11, which following deprotection, affording 12, and condensation of the acid group with an amine in the presence of DCC provides compound of the invention If.

Scheme 4 10 Jco2-P \ 10 deprotection z base L base ^ 11 Sz3 z /- f - $ N'C02H CONRRa CO-NR7R8 or R H"H 12 Scheme 5 describes the treatment of the pyrimidine core intermediate 4 with a compound 13 (having two leaving groups, L and L') in the presence of a base such as sodium hydride thereby providing intermediate 14. The reaction of 14 with a urea in the presence of a base such as sodium hydride provides intermediate 15. Hydrolysis of 15 provides compound of the invention Ig.

Alternatively, treatement of core intermediate 4 with a compound 16 having a leaving group and a protected alcohol provides intermediate 17, which upon deprotection provides intermediate 18. Reaction of 18 with an alkane or arene sulfonyl chloride (such as methane sulfonyl chloride or toluene sulfonyl chloride) in the presence of a base such as triethylamine provides intermediate 19 which can be reacted with urea 19 to provide product of the invention Ig.

Scheme 5

z1 ... . , - ., Z3 13 2 R J base I N XCH3 14 15 Z2 3 hydrolysis Il R2 NJ-N'K '6'R7 R1 H H 19 z1 Z3 J, L-O-P 16 deprotection Rz J_P OH 4 H 17 18 ZZ"0 r A R 17 z z2z3 CI-S02R 2 base J. R1 H 19 Finally, as illustrated in Scheme 6, a compound of the invention Ih may contain functionality in the RI group, such an azide, which can be further modified.

For example, reduction of the azide group of Ih with hydrogen in the presence of a palladium catalyist provides product of the invention Ig.

Scheme 6 z f f Cz3 reduce R N -XCH3 Ih li Preferred Compounds Preferred compounds within the scope of formula (I), including enantiomers, diastereomers, solvates and salts thereof, are those in which : J is alkylene optionally substituted with Zla, Z2a and/or one or more Z3a (especially alkyl) ; and/or R1 is alkyl optionally substituted with Zlb, Zn and/or one or more Z3b ; and/or R2 is C (O) R5 or C (O) ORS (especially Co2R5) ; and/or R3 is -N(R6) C (O) R7, -N(R6) C (O) 0 R7-N (R6)C(O)-NR7R8 or -NR6S(O)2R7 ; and/or R4 is hydrogen or alkyl ; and/or A is aryl optionally substituted with Zla, Z2a and/or one or more Z3a (especially a 1 group of formula' More preferred compounds are those in which R3 is -N(R6)C(O)R7, Especially preferred compounds where R3 is -N(R6)C(O)R7 are those in which J is n-propyl ; R6 is hydrogen or alkyl ; and R7 is selected from

Even more especially preferred compounds within this scope are those in which R1 is methyl; and/or R2 is C (O) O (alkyl) wherein alkyl is selected from methyl, ethyl and isopropyl (especially isopropyl).

Alternatively preferred compounds where R3 is-N (R6) C (O) R7 are those in which R2 is C (O) O (alkyl) wherein alkyl is selected from methyl, ethyl and isopropyl (especially isopropyl).

Other preferred compounds are those in which R3 is-N (R6) C (O) OR7.

Particularly preferred compounds within this scope are those in which R7 is selected from

Other preferred compounds are those in which R3 is -N(R6) S (O) 2R7.

Particularly preferred compounds within this scope are those in which R7 is selected from

Other preferred compounds are those in which R3 is-N (R6) C (O) NR7Rg.

Particularly preferred compounds within this scope are those in which R3 is selected from Other preferred compounds within the scope of formula (I) are those in which A is aryl optionally substituted with zl, Z2 and/or one or more Z3 ; and R3 is a group of formula Other preferred compounds within the scope of formula (I) are those in which A is aryl optionally substituted with zl, Z2 and/or one or more Z3 ; and R3 is a group of formula

Particularly preferred compounds within this scope are those in which J is methylene; and R3 is selected from Especially preferred compounds within the scope of formula (I) are selected from: (i) 1,2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl] - 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- (Benzoylmethylamino) propyl] -1, 2,3, 6-tetrahydro-4-methyl-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (phenylacetyl) aminolpropyl]-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (Diphenylacetyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (l-oxo-3- phenylpropyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

1- [3-[[(4-Chlorophenyl)acetyl]methylamino]propyl]-1,2,3,6-tetr ahydro-4- <BR> <BR> methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylicacid, 1-methylethyl ester; 1, 2, 3, 6-Tetraliydro-4-methyl-1- [3- [methyl (4- pyridinylcarbonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (3- pyridinylcarbonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (2-Furanylcarbonyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-TetrahydrQ-1- [3- [ (5-isoxazolylcarbonyl) methylamino] propyl] -4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (Cyclopentylacetyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 1- [3- [ (Cyclohexylcarbonyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (2-methylbenzoyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidW ecarboxylic acid, 1-methylethyl ester; 1- [3- [ (3-Fluorobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (2-Fluorobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (4-Fluorobenzoyl) methylamino] propyl] -1, 2, 3, 6-tetrahydro-4-metliyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl (2-thienylacetyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methyletliyl ester; 1- [3- [ (3-Cyclopentyl-1-oxopropyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (3-Cyanobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (4-Cyanobenzoyl) methylamino] propyl]-1, 2, 3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

1, 2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl [ (2E)-l-oxo-3-phenyl-2- propenyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (4-Ethylbenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-l- [3- [ (2-methoxybenzoyl) methylamino] propyl]-4-methyl- 6-(3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-1-[3-[(3-methoxybenzoyl)methylamino] propyl] -4-methyl- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl (phenoxyacetyl) amino] propyl]-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[(4-Fluorophenyl) acetyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (3-Chlorobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[(2,4-Difluorobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (2, 3-Difluorobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (2- phenylcyclopropyl) carbonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2, 3,6-Tetrahydro-4-methyl-1-[3-[methyl (4-propylbenzoyl) amino] propyl] -6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl (l-oxo-2- phenylbutyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[(1,3-Benzodioxol-5-ylcarbonyl)methylamino]propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-l- [3- [ [ (3-methoxyphenyl) acetyl] methylamino] propyl] -4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

1, 2,3, 6-Tetrahydro-1-[3-[[(4-methoxyphenyl) acetyl] methylamino] propyl]-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl [(phenylmethoxy) acetyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (2- quinoxalinylcarbonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (Benzo [b] thien-2-ylcarbonyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[4-(1,1-Dimethylethyl) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (3, 5-Dimethoxybenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 1-[3-[[(4-Chlorophenoxy) acetyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [3- (trifluoromethyl) benzoyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (3, 4-Dichlorobenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[([1, 1'-Biphenyl] -4-ylcarbonyl) methylamino] propyl] -1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[[1-(4-Chlorophenyl) cyclopentyl] carbonyl] methylamino] propyl]- 1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-1- [3- [ (4-iodobenzoyl) methylamino] propyl]-4-methyl-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

1- [3- [ (3, 4-Dimethylbenzoyl) methylamino] propyl]-1, 2,3, 6-tetrahydro-4- <BR> <BR> methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (2, 3-Dimethylbenzoyl) methylamino] propyl] -1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl [ [6- (4-methylphenoxy)-3- pyridinyl] carbonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl (l-oxo-4- phenoxybutyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl (l- naphthalenylacetyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [Acetyl (phenylmethyl) amino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (3-phenoxybenzoyl) amino] propyl] - 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (3- phenoxyphenyl) acetyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl] - 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 1,2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl] - 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl] - 2-oxo-6- (2-pyridinyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl (4-phenoxybenzoyl) amino] propyl]- 6- (6-methyl-2-pyridinyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl]- 6- (2-methyl-4-thiazolyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [4- (2- phenoxyethoxy) benzoyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[4-(4- hydroxyphenoxy) benzoyl] methylamino] propyl] -4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[4-(4-Chlorophenoxy) benzoyl] methylamino] propyl]-6- (3-chlorophenyl)- 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Clilorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [4- (4- methylphenoxy) benzoyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 6-(3-Chlorophenyl)-1-[3-[[4-(cyclohexyloxy) benzoyl] methylamino] propyl] - 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 6-(3-Chlorophenyl)-1-[3-[[(4'-ethy[1, 1'-biphenyl] -4- yl) carbonyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ (4-Benzoylbenzoyl) methylamino] propyl]-6- (3-chlorophenyl)-1, 2,3, 6- tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1-[3-[[(2, 3-dihydro-5- benzofuranyl) carbonyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1- [3- [ (2-dibenzofuranylcarbonyl) methylamino] propyl] - 1,2, 3, 6-tetrahydro-4-metliyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-l- [3- [methyl [4- [ [2-oxo-5- (trifluoromethyl)-1 (2Fl)-pyridinyl] methyl] benzoyl] amino] propyl]-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1- [3- [ (4-ethoxybenzoyl) methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1-[3-[[4-(1, 1- dimethylethoxy) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [4- (trifluoromethoxy) benzoyl]amino]propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl [4- (phenylmethoxy) benzoyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl (4- phenoxybenzoyl) amino] propyl] -2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetraliydro-4-metliyl-l- [3- [methyl (4- phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-l- [3- [ [4- (2-cyclohexen-l- yloxy) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-1-[3-[(4- phenoxybenzoyl) amino] propyl]-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3- [methyl (phenoxyacetyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[(5-methyl-3- phenyl-4-isoxazolyl) carbonyl]amino]propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A ; 6-(3-Chloropenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[(2- phenylcyclopropyl) carbonyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A ; 6-(3-Chlorophenyl)-1-[3-[[4-(2, 4- difluorophenoxy) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl- 2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A ; 6-(3-Chlorophenyl)-1-[3-[(4-ethoxybenzoyl) methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [4- [[(phenylamino) carbonyl] amino] benzoyl] amino] propyl]-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B;

6- (3-Chlorophenyl)-1-[3-[[4-(1,3-dihydro-1,3-dioxo-2H-isoindol -2- yl) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6-(3-Chlorophenyl)-1-[3-[[4-(4-fluorophenoxy) benzoyl] methylamino] propyl]- 1,2, 3,6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B ; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (l-oxo-3, 3- diphenylpropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (l-oxo-4- phenylbutyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (l-oxo-3- phenoxypropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B; 6-(3-Chlorophenyl)-1,2, 3, 6-tetrahydro-4-methyl-1-[3-[methyl(1-oxo-3- phenylpropyl) amino] propyl] -2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[4-(4,5-dihydro-3-methyl-5-oxo-1H-pyr azol-1- yl) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (4- phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B; 6- (3-Chlorophenyl) -1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (phenoxyacetyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[(5-methyl-3- phenyl-4-isoxazolyl) carbonyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-l- [3- [methyl [ (2- phenylcyclopropyl) carbonyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-l- [3- [ [4- (2, 4- difluorophenoxy) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl- 2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B;

6-(3-Chlorophenyl)-1-[3-[(4-ethoxybenzoyl)methylamino]propyl ]-1, 2,3, 6- tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [4- [ [ (phenylamino) carbonyl] amino] benzoyl]amino]propyl]-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1-[3-[[4-(1,3-dihydro-1,3-dioxo-2H-isoindol -2- yl) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A 6- (3-Chlorophcnyl)-l- [3- [ [4- (4-fluorophenoxy) benzoyl] methylamino] propyl] - 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [metliyl (l-oxo-3, 3- diphenylpropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl(1-oxo-4- phenylbutyl) amino] propyl] -2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl(1-oxo-3- phenoxypropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1-[3-[[4-(4,5-dihydro-3-methyl-5-oxo-1H-pyr azol-1- yl) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl (4- phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 1,2, 3, 6-Tetrahydro-4-methyl-6-(3-nitrophenyl)-2-oxo-1-[3-(2-oxo-3- phenyl-1- imidazolidinyl) propyl] -5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-1- [3- (2-oxo-3-phenyl- 1 (2H)-pyridinyl) propyl] -5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [2, 3-Dihydro-2-oxo-3- (phenylmethyl)-lH-imidazol-1-yl] propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester;

1-[3-(1,5-Dihydro-5-oxo-1-phenyl-4H-1, 2,4-triazol-4-yl) propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1- [3- (4, 5-Dihydro-5-oxo-4-phenyl-1 H-1, 2, 4-triazol-1-yl) propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1- [3- (4, 5-Dihydro-5-oxo-4-phenyl-lH-tetrazol-1-yl) propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-6-(3-nitrophenyl)-2-oxo-1-[3-[2-oxo-3- (phenylmethyl)-l-imidazolidinyl] propyl]-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1- [3- (1, 3-Dihydro-1, 3-dioxo-2H-isoindol-2-yl) propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [3- (4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl] propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[3-(4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl]propyl]-1, 2,3, 6-tetraliydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 1- [3- [3- (4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl] propyl] -1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrinidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 1, 2, 3, 6-Tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-1- [3- (4-phenyl-1 H- imidazol-l-yl) propyl]-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-6- (3-mtrophenyl)-2-oxo-l- [3- (2-oxo-3-phenyl-l- imidazolidinyl) propyl]-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1- [3- [3- (2, 4-difluorophenyl)-2-oxo-1- imidazolidinyl] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1- [ 3- [3- [4- ( 1, 1-dimethylethyl) phenyl]-2-oxo-1- imidazolidinyl] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-l- [3- [3- [3- (l, l-dimethylethyl) phenyl]-2-oxo-l- imidazolidinyl] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester;

l- [3- [3- [4- (4-Chlorophenoxy) phenyl]-2-oxo-l-imidazolidinyl] propyl]-6- (3- chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[[(4- fluorophenyl) amino] carbonyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4- methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [(phenylamino) carbonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[([1,1'-Biphenyl]-4-ylamino) carbonyl] methylamino] propyl]-6- (3- chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[[[(4- methoxyphenyl) methyl] amino] carbonyl] methylamino] propyl] -4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [ [ (4- phenoxyphenyl) amino] carbonyl] amino] propyl]-2-oxo-5-pyrimiduiecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1-[3-[methyl (phenoxycarbonyl) amino] propyl] -6- (3-nitrophenyl) -2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ [ (1, 1-Dimethylethoxy) carbonyl] (phenyhnethyl) amino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [ (phenylmethoxy) carbonyl] amino] propyl]-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [(phenylmethoxy) carbonyl] amino] propyl]-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[(4- methoxyphenoxy) carbonyl] methylamino] propyl] -4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[(4- methoxyphenoxy) carbonyl] methylamino] propyl]-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B.

1, 2,3, 6-Tetrahydro-4-methyl-1- [3- [methyl (phenylsulfonyl) amino] propyl] -6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [(phenylmethyl) sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-1- [3- [methyl (2-thienylsulfonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (3- methylphenyl) sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (2- methylphenyl) sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (4- methylphenyl) sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ [ (2-Fluorophenyl) sulfonyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[(3-Fluorophenyl)sulfonyl]methylamino] propyl] -1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ [ (E)-2- phenylethenyl] sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [ [ (2, 5-Dimethylphenyl) sulfonyl] methylamino] propyl-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-1-[3-[[(4-methoxyphenyl)sulfonyl] methylamino] propyl]-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[(4-Chlorophenyl)sulfonyl]methylamino]propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

1, 2,3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ [4- (1- methylethyl) phenyl] sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (4- propylphenyl) sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[(4-Carboxyphenyl)sulfonyl]methylamino]propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 5- (1- methylethyl) ester; 1-[3-[[(3-Carboxyphenyl)sulfonyl]methylamino]propyl]-1, 2,3, 6-tetrahydro-4- methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 5- (1- methylethyl) ester; 1-[3-[[(2-Chloro-6-methylphenyl)sulfonyl]methylamino]propyl] -1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; , 2,3, 6-Tetrahydro-4-methyl-1-[3-[methyl(1- naphthalenylsulfonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-1-[3-[methyl (2- naphthalenylsulfonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl (8- quinolinylsulfonyl) amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[(3-Chloro-4-fluorophenyl)sulfonyl]methylamino]propyl] -1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrinidinecarboxylic acid, 1- methylethyl ester; 1-[3-[[[4-(1,1-Dimethylethyl) phenyl] sulfonyl] methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1- [3- [ [ [4- (Acetylamino) phenyl] sulfonyl] methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1,2, 3, 6-Tetrahydro-1-[3-[[[2- (methoxycarbonyl) phenyl] sulfonyl] methylamino] propyl]-4-methyl-6- (3- nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

1- [3- [ (2, 1, 3-Benzothiadiazol-4-ylsulfonyl) methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1-[3-[[(2,5-Dimethoxyphenyl)sulfonyl] methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-1-[3-[methyl[[3- (trifluoromethyl) phenyl] sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[3-(4-fluorophenyl)-1- oxopropyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1-[3-[[(4-fluorophenoxy) acetyl] methylamino] propyl] - 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[3-(4- methylphenyl)-1-oxopropyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[(4- methylphenoxy) acetyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[1-oxo-3-[4- (trifluoromethyl) phenyl] propyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetraliydro-4-methyl-1- [3- [methyl [ [4- (1- methylethyl) phenoxy] acetyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[3-(3- methylphenyl)-1-oxopropyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[(3- methoxyphenoxy) acetyl] methylamino] propyl]-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[3-(4-fluorophenoxy)-1- oxopropyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester;

6- (3-Chlorophenyl)-1-[3-[[3-(2,4-difluorophenoxy)-1- oxopropyl]methylamino]propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1- [3- [ [3- (3-methoxyphenoxy)-1- oxopropyl] methylamino] propyl]-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [3- (1- naphthalenyloxy)-1-oxopropyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1- [3- [ [5- (4-fluorophenyl)-1- oxopentyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[4-(1,1- dimethylethyl) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl [ [4- (trifluoromethyl) phenyl] sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; and 1-[3-[[(2, 3-Dichlorophenyl) sulfonyl] methylamino] propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; or (ii) enantiomers, diastereomers, solvates and salts of (i) thereof.

Even more especially preferred compounds within the foregoing scope of compounds are selected from: (i) 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl]- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester ; 1, 2,3, 6-Tetrahydro-4-methyl-1- [3- [methyl (3-phenoxybenzoyl) amino] propyl]- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1-[3-[methyl[(3- phenoxyphenyl) acetyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester;

1, 2,3, 6-Tetrahydro-4-methyl-1-[3-[methyl (4-phenoxybenzoyl) amino] propyl]- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 1, 2,3,6-Tetrahydro-4-methyl-1-[3-[methyl (4-phenoxybenzoyl) amino] propyl] - 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[4-(4- hydroxyphenoxy) benzoyl] methylamino] propyl]-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[4-(4-Chlorophenoxy) benzoyl] methylamino] propyl]-6- (3-chlorophenyl)- 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[4-(4- methylphenoxy) benzoyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1- [3- [ (4-Benzoylbenzoyl) methylamino] propyl]-6- (3-chlorophenyl)-1, 2,3, 6- tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[4-[[2-oxo-5- (trifluoromethyl)-1 (2H)-pyridinyl] methyl] benzoyl] amino] propyl]-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1-[3-[(4-ethoxybenzoyl) methylamino] propyl]-1, 2,3, 6- tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1- [3- [ [4- (1, 1- dimethylethoxy) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-l- [3- [methyl [4- (trifluoromethoxy) benzoyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl [4- (phenylmethoxy) benzoyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (4- phenoxybenzoyl) amino] propyl] -2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B;

6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl (4- phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1- [3- [ [4- (2-cyclohexen-l- yloxy) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-1-[3-[(4- phenoxybenzoyl) amino] propyl]-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1-[3-[[4-(2, 4- difluorophenoxy) benzoyl]methylamino]propyl]-1, 2,3, 6-tetrahydro-4-methyl- 2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1- [3- [ [4- (4-fluorophenoxy) benzoyl] methylamino] propyl]- 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-l- [3- [methyl (l-oxo-3, 3- diphenylpropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B ; 6-(3-Chlorophenyl)-1-[3-[[4-(2, 4- difluorophenoxy) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl- 2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6-(3-Chlorophenyl)-1-[3-[[4-(4-fluorophenoxy) benzoyl] methylamino] propyl]- 1,2, 3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl (4- phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 1,2, 3, 6-Tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-l- [3- (2-oxo-3-phenyl-l- imidazolidinyl) propyl]-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [3- (4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl] propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1- [3- [3- (4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl] propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A ;

1- [3- [3- (4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl] propyl] -1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 1,2, 3, 6-Tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-1- [3- (2-oxo-3-phenyl-1- imidazolidinyl) propyl]-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1,2, 3, 6-Tetrahydro-4-methyl-1- [3- [methyl [ (phenylamino) carbonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[([1, 1'-Biphenyl] -4-ylamino) carbonyl] methylamino] propyl]-6- (3- chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3-[[[[(4- methoxyphenyl) methyl] amino] carbonyl] methylamino] propyl]-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[[(4- phenoxyphenyl) amino] carbonyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 1-[3-[[[4-(1,1-Dimethylethyl) phenyl] sulfonyl] methylamino] propyl] -1, 2,3, 6- tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 1- [3- [ [ [5- (Dimethylamino)-1-naphthalenyl] sulfonyl] methylamino] propyl] - 1, 2,3, 6-tetrahydro-4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, trifluoroacetic acid salt (1 : 1) ; 1,2, 3,6-Tetrahydro-4-methyl-1-[3-[methyl[[4-(2- pyridinyloxy) phenyl] sulfonyl] amino] propyl]-6- (3-nitrophenyl)-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester, trifluoroacetic acid salt (1 : 1) ; 4-[(2-Aminoethoxy) methyl]-6-(2-chlorophenyl)-1, 2,3, 6-tetrahydro-1- [3- [methyl (l-oxo-3-phenylpropyl) amino] propyl] -2-oxo-5-pyrimidinecarboxylic acid, ethyl ester; 4-[(2-Aminoethoxy)methyl]-6-(2-chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3- [methyl (l-oXo-3-phenylpropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, ethyl ester, enantiomer A; 4-[(2-Aminoethoxy)methyl]-6-(2-chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3- [methyl (l-oxo-3-phenylpropyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, ethyl ester, enantiomer B;

4-[(2-Aminoethoxy)methyl]-6-(2-chlorophenyl)-1, 2,3, 6-tetrahydro-1-[3- [methyl (4-phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, ethyl ester; 4-[(2-Aminoethoxy)methyl]-6-(3,5-dichlorophenyl)-1, 2,3, 6-tetrahydro-1-[3- [methyl (4-phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 4-[(2-Aminoethoxy)methyl]-6-(3,5-dichlorophenyl)-1, 2,3, 6-tetrahydro-1-[3- [methyl (4-phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, methyl ester; 4-[(2-Aminoethoxy)methyl]-6-(3,5-dichlorophenyl)-1, 2,3, 6-tetrahydro-1-[3- [methyl (4-phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, ethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-l- [ [3- [ [methyl (3- phenylpropyl) amino] carbonyl] phenyl] methyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[3-(4-fluorophenyl)-1- oxopropyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[3-(4- methylphenyl)-l-oxopropyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-metliylethyl ester, enantiomer B ; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[(4- methylphenoxy) acetyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[1-oxo-3-[4- (trifluoromethyl) phenyl] propyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6-(3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1-[3-[methyl[[4-(1- methylethyl) phenoxy] acetyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; 6- (3-Chlorophenyl)-1-[3-[[5-(4-fluorophenyl)-1- oxopentyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2-oxo-5- pyrimidinecarboxylic acid, 1-methylethyl ester; and 6-(3-Chlorophenyl)-1- [3- [ [4- (1, 1- dimethylethyl) benzoyl] methylamino] propyl]-1, 2,3, 6-tetrahydro-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; or

(ii) enantiomers, diastereomers, solvates and salts of (i) thereof.

Most especially preferred compounds within the foregoing scope of compounds are those selected from (i) 1, 2,3, 6-Tetrahydro-4-methyl-1-[3-[methyl (4-phenoxybenzoyl) amino] propyl] - 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 1, 2,3, 6-Tetrahydro-4-methyl-l- [3- [methyl (4-phenoxybenzoyl) amino] propyl]- 6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-l- [3- [methyl (4- phenoxybenzoyl) amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetraliydro-4-methyl-1- [3- [methyl (4- phenoxybenzoyl) amino] propyl] -2-oxo-5-pyrimidinecarboxylic acid, 1- methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1-[3-[[4-(2, 4- difluorophenoxy) benzoyl] methylamino] propyl]-1, 2,3, 6-tekahydro-4-methyl- ( 2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 6-(3-Chlorophenyl)-1-[3-[[4-(2, 4- difluorophenoxy) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl- 2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; l- [3- [3- (4-Ethoxyphenyl)-2-oxo-l-imidazolidinyl] propyl]-l, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer A; 1- [3- [3- (4-Ethoxyphenyl)-2-oxo-1-imidazolidinyl] propyl]-1, 2,3, 6-tetrahydro- 4-methyl-6- (3-nitrophenyl)-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [3- (4- methylphenyl)-1-oxopropyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester, enantiomer B; 6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [l-oxo-3- [4- (trifluoromethyl) phenyl] propyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester;

6- (3-Chlorophenyl)-1, 2,3, 6-tetrahydro-4-methyl-1- [3- [methyl [ [4- (1- methylethyl) phenoxy] acetyl] amino] propyl]-2-oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; and 6-(3-Chlorophenyl)-1-[3-[[4-(1, 1- dimethylethyl) benzoyl] methylamino] propyl]-l, 2,3, 6-tetrahydro-4-methyl-2- oxo-5-pyrimidinecarboxylic acid, 1-methylethyl ester; or (ii) enantiomers, diastereomers, solvates and salts of (i) thereof.

Utility The compounds of formula I and salts thereof are antagonists of calcium channels (especially T-type and/or L-type calcium channels) and are useful in treatment of calcium channel-dependent disorders. They are thus useful as antihypertensive agents. By the administration of a composition having one (or a combination) of the compounds of this invention, the blood pressure of a hypertensive mammalian (e. g. , human) host is reduced. They are also useful in portal hypertension, hypertension secondary to treatment with erythropoietin and low renin hypertension.

The compounds of the present invention are also useful in the treatment of disorders related to renal, glomerular and mesangial cell function, including acute (such as ischemic, nephrotoxic, or glomerulonephritis) and chronic (such as diabetic, hypertensive or immune-mediated) renal failure, diabetic nephropathy, glomerular injury, renal damage secondary to old age or related to dialysis, nephrosclerosis (especially hypertensive nephrosclerosis), nephrotoxicity (including nephrotoxicity related to imaging and contrast agents and to cyclosporine), renal ischemia, primary vesicoureteral reflux, glomerulosclerosis and the like. The compounds of this invention are also useful in the treatment of disorders related to paracrine and endocrine function. The compounds of this invention are also useful in the treatment of diabetic nephropathy, hypertension-induced nephropathy, and IGA-induced nephropathy.

The compounds of the present invention are also useful in the treatment of endotoxemia or endotoxin shock as well as hemorrhagic shock. The compounds of the present invention are also useful in alleviation of pain, including neuropathic pain, peripheral pain and pain associated with cancer, such as the pain associated with

prostate cancer, and bone pain associated with bone cancer. The compounds of the present invention are further useful in the prevention and/or reduction of end-organ damage associated with cell-proliferation.

The compounds of the present invention are also useful in hypoxic and ischemic disease and as anti-ischemic agents for the treatment of, for example, cardiac, renal and cerebral ischemia and reperfusion (such as that occurring following cardiopulmonary bypass surgery), coronary and cerebral vasospasm, and the like.

In addition, the compounds of this invention are also useful as anti-arrhythmic agents; anti-anginal agents; anti-fibrillatory agents; anti-asthmatic agents; anti- atherosclerotic and anti-arteriosclerotic agents (including anti-transplantation arteriosclerotic agents); additives to cardioplegic solutions for cardiopulmonary bypasses; adjuncts to thrombolytic therapy; and anti-diarrheal agents. The compounds of this invention may be useful in therapy for myocardial infarction; therapy for peripheral vascular disease (e. g. , Raynaud's disease, intermittent claudication and Takayashu's disease); treatment of cardiac hypertrophy (e. g., hypertrophic cardiomyopathy); treatment of primary pulmonary hypertension (e. g., plexogenic, embolic) in adults and in the newborn and pulmonary hypertension secondary to heart failure, radiation and chemotherapeutic injury, or other trauma ; treatment of central nervous system vascular disorders, such as stroke, migraine and subarachnoid hemorrhage; treatment of central nervous system behavioral disorders; treatment of gastrointestinal diseases such as ulcerative colitis, Crohn's disease, gastric mucosal damage, ulcer, inflammatory bowel disease and ischemic bowel disease; treatment of gall bladder or bile duct-based diseases such as cholangitis; treatment of pancreatitis; regulation of cell growth; treatment of benign prostatic hypertrophy ; restenosis following angioplasty or following any procedure including transplantation and stenting; therapy for congestive heart failure including inhibition of fibrosis ; inhibition of left ventricular dilatation, remodeling and dysfunction ; and treatment of hepatotoxicity and sudden death. The compounds of this invention are useful in the treatment of sickle cell disease including the initiation and/or evolution of the pain crises of this disease; treatment of the deleterious consequences of tumors such as hypertension resulting from hemangiopericytoma; treatment of early and advanced liver disease and injury including attendant complications (e. g.,

hepatotoxicity, fibrosis and cirrhosis); treatment of spastic diseases of the urinary tract and/or bladder; treatment of hepatorenal syndrome; treatment of immunological diseases involving vasculitis such as lupus, systemic sclerosis, mixed cryoglobulinemia; and treatment of fibrosis associated with renal dysfunction and hepatotoxicity. The compounds of this invention are useful in therapy for metabolic and neurological disorders; cancer; insulin-dependent and non insulin-dependent diabetes mellitus; neuropathy ; retinopathy; epilepsy; hemorrhagic and ischemic stroke ; bone remodeling; psoriasis; and chronic inflammatory diseases such as arthritis, rheumatoid arthritis, osteoarthritis, sarcoidosis and eczematous dermatitis (all types of dermatitis).

The compounds of this invention are additionally useful in the treatment of disorders involving bronchoconstriction and disorders of chronic or acute pulmonary inflammation such as chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome (ARDS).

The compounds of this invention are also useful in the treatment of sexual dysfunction in both men (erectile dysfunction, for example, due to diabetes mellitus, spinal cord injury, radical prostatectomy, psychogenic etiology or any other cause) and women by improving blood flow to the genitalia, especially, the corpus cavernosum.

The compounds of this invention are also useful in the treatment of dementia, including Alzheimer's dementia, senile dementia and vascular dementia.

Additionally the compounds of the present invention are further useful in the reduction of general morbidity and/or mortality as a result of the above utilities.

The present invention thus provides methods for the treatment of these disorders, comprising the step of administering to a subject in need thereof at least one compound of the formula I in an amount effective therefor. Other therapeutic agents such as those described below may be employed with the inventive compounds in the present methods. In the methods of the present invention, such other therapeutic agent (s) may be administered prior to, simultaneously with or following the administration of the compound (s) of the present invention.

The effective amount of a compound of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts

for a human of from about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably from about 0.5 to about 25 mg/kg of body weight (or from about 1 to about 2500 mg, preferably from about 5 to about 500 mg) of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats and the like, subject to calcium channel-dependent disorders.

The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the formula I capable of treating a calcium channel-dependent disorder in an amount effective therefor, and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions of the present invention may contain other therapeutic agents as described below, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc. ) according to techniques such as those well known in the art of pharmaceutical formulation or called for by accepted pharmaceutical practice.

The compounds of the formula I may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrastemal injection or infusion techniques (e. g. , as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The present compounds may, for example, be administered in a form suitable for immediate release or extended

release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds may also be administered liposomally. For example, the active substance can be utilized in a composition such as tablet, capsule, solution or suspension containing about 5 to about 500 mg per unit dosage of a compound or mixture of compounds of formula I or in topical form for wound healing (0.01 to 5% by weight compound of formula I, 1 to 5 treatments per day). They may be compounded in a conventional manner with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc. , or with a topical carrier.

The compounds of formula I can also be formulated in compositions such as sterile solutions or suspensions for parenteral administration. About 0.1 to 500 milligrams of a compound of formula I may be compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is preferably such that a suitable dosage in the range indicated is obtained.

Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art.

Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those formulating the present compound (s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). Such formulations may also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e. g. , Gantrez), and agents to

control release such as polyacrylic copolymer (e. g. , Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono-or diglycerides, and fatty acids, including oleic acid.

Exemplary compositions for rectal administration include suppositories which may contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.

Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene). For example, the compounds of the invention may be administered topically to treat peripheral vascular diseases and as such may be formulated as a cream or ointment.

The compounds of the present invention may be employed alone or in combination with each other and/or other suitable therapeutic agents. For example, the compounds of this invention can be formulated in combination with endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; thromboxane receptor antagonists such as ifetroban ; potassium channel openers; thrombin inhibitors (e. g., hirudin and the like); growth factor inhibitors such as modulators of PDGF activity; platelet activating factor (PAF) antagonists; anti-platelet agents such as GPIIb/IIIa blockers (e. g., abciximab, eptifibatide, and tirofiban), P2Y (AC) antagonists (e. g., clopidogrel, ticlopidine and CS-747), and aspirin; anticoagulants such as warfarin, low molecular weight heparins such as enoxaparin, Factor VIIa inhibitors, and Factor Xa inhibitors such as those described in U. S. Serial No. 09/496,571 filed February 2,

2000; renin inhibitors; angiotensin converting enzyme (ACE) inhibitors such as captopril, zofenopril, fosinopril, ceranapril, alacepril, enalapril, delapril, pentopril, quinapril, ramipril, lisinopril and salts of such compounds; neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors) such as omapatrilat and gemopatrilat; HMG CoA reductase inhibitors such as pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a. k. a. itavastatin, or nisvastatin or nisbastatin) and ZD-4522 (a. k. a. rosuvastatin, or atavastatin or visastatin); squalene synthetase inhibitors; fibrates ; bile acid sequestrants such as questran; niacin; anti- atherosclerotic agents such as ACAT inhibitors; MTP inhibitors such as those described in U. S. Serial No. 09/007, 938 filed January 16,1998 ; calcium channel blockers such as amlodipine besylate; potassium channel activators; alpha-adrenergic agents, beta-adrenergic agents such as carvedilol and metoprolol; antiarrhythmic agents, such as dofetilide, quinidine, ibutilide, propofanone, amiodarone; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide or benzothiazide as well as ethacrynic acid, tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds; thrombolytic agents such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase and anisoylated plasminogen streptokinase activator complex (APSAC); anti-diabetic agents such as biguanides (e. g. metformin), glucosidase inhibitors (e. g. , acarbose), insulins, meglitinides (e. g., repaglinide), sulfonylureas (e. g., glimepiride, glyburide, and glipizide), biguanide/glyburide combinations such as those described in U. S. Serial No.

09/432,465 filed November 3,1999 and U. S. Serial No. 09/460,920 filed December 14,1999 ; thiozolidinediones (e. g. troglitazone, rosiglitazone and pioglitazone), and PPAR-gamma agonists; mineralocorticoid receptor antagonists such as spironolactone and eplerenone ; growth hormone secretagogues such as those described in U. S. Serial No. 09/417,180 filed October 12,1999 and U. S. Serial No. 09/506,749 filed February 18,2000 ; aP2 inhibitors such as those described in U. S. Serial No. 09/391,053 filed September 7,1999 and U. S. Serial No. 09/390,275 filed September 7,1999 digitalis; ouabian; non-steroidal antiinflammatory drugs (NSAIDS) such as aspirin and ibuprofen; phosphodiesterase inhibitors such as PDE III inhibitors (e. g. , cilostazol)

and PDE V inhibitors (e. g. , sildenafil); protein tyrosine kinase inhibitors; antiinflammatories ; antiproliferatives such as methotrexate, FK506 (tacrolimus, Prograf), mycophenolate and mofetil; chemotherapeutic agents; immunosuppressants; anticancer agents and cytotoxic agents (e. g. , alkylating agents, such as nitrogen mustards, alkyl sulfonates, nitrosoureas, ethylenimines, and triazenes); antimetabolites such as folate antagonists, purine analogues, and pyrimidine analogues; antibiotics, such as anthracyclines, bleomycins, mitomycin, dactinomycin, and plicamycin; enzymes, such as L-asparaginase; farnesyl-protein transferase inhibitors; hormonal agents, such as glucocorticoids (e. g. , cortisone), estrogens/antiestrogens, androgens/antiandrogens, progestins, and luteinizing hormone-releasing hormone anatagonists, octreotide acetate; microtubule-disruptor agents, such as ecteinascidins or their analogs and derivatives; microtubule-stabilizing agents such as paclitaxel (Taxol (D), docetaxel (Taxotere (D), and epothilones A-F or their analogs or derivatives; plant-derived products, such as vinca alkaloids, epipodophyllotoxins, taxanes ; and topoisomerase inhibitors; prenyl-protein transferase inhibitors; and miscellaneous agents such as, hydroxyurea, procarbazine, mitotane, hexamethyhnelamine, platinum coordination complexes such as cisplatin and carboplatin); cyclosporins; steroids such as prednisone or dexamethasone; gold compounds; cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-alpha inhibitors such as tenidap; anti-TNF antibodies or soluble TNF receptor such as etanercept (Enbrel) rapamycin (sirolimus or Rapamune), leflunimide (Arava); and cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Celebrex) and rofecoxib (Vioxx).

The compounds of this invention may also be formulated with, or useful in conjunction with, antifungal and immunosuppressive agents such as amphotericin B, cyclosporins and the like to counteract the glomerular contraction and nephrotoxicity secondary to such compounds. The compounds of this invention may also be used in conjunction with hemodialysis.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range. The above other therapeutic agents, when employed in combination with the compounds of the present

invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.

The following assays may be employed in ascertaining the degree of activity of a compound as an antagonists of calcium channels (especially T-type and/or L-type calcium channels). Compounds described in the following Examples have demonstrated measurable activity as calcium channel antagonists.

Aortic ring protocol: Male Sprague-Dawley rats (250-300 g) were euthanized by C02 and cervical dislocation. The thoracic aorta was removed and placed in physiological salt solution (PSS) of the following composition, in mM: 118.4 NaCl, 4.7 KC1, 1.2 MgCk, 1.2 KH 2PO4, 1. 9 CaCl2, 25.0 NaHC03, and 10.1 glucose. The aorta was cleaned of adherent connective tissue and cut into rings approximately 3 mm wide. The endothelium was removed from each ring by placing the ring on a dissecting probe and gently rolling on PSS-moistened filter paper. Each rat aortic ring was mounted for isometric force recording on stainless steel wires in a 10 ml organ chamber between a micrometer for control of tissue length and a GRASS FT-03 force transducer. Mechanical responses were recorded using a PowerLab'@ data acquisition system. The organ chambers contained PSS aerated with 95% O2, 5% C02 to maintain the pH at 7.4. The experiments were performed at 37°C. The tissues were gradually stretched over a 2 hr equilibration period to approximately 2 g preload.

Compounds were tested for the ability to produce relaxation of aortic rings that were contracted with 80 mM KC1.

Patch-clamp electropvsiology : T-and L-type calcium currents were studied using cell lines stably expressing the cloned human T- (alphalH) and L-type calcium ion channel genes. Membrane current recordings were made with Axopatch 200A and 200B integrating patch-clamp amplifiers (Axon Instruments, Foster City, CA) using the whole-cell variant of the patch-clamp technique. The bath solution, which replaced the cell culture media during experiments, for T-type calcium current experiments contained (in mM): 140 NaCI, 5 CaCl2, 4 KC1, 1 MgCl2, 10 Glucose, 10 HEPES (pH 7. 35, NaOH). The patch

pipette filling solution used T-type calcium current experiments experiments contained (in mM) : 130 KC1, 1 CaCl2, 1 MgCl2, 5 ATP-K2,10 EGTA, 10 HEPES (pH 7.2, KOH). The bath solution for L-type calcium current experiments contained (in mM) : 103 NaCl, 30 BaCl2, 4 CsCl, 1 MgC12, 10 glucose, 10 HEPES (pH 7.35, NaOH). The pipette solution used in L-type calcium current experiments contained (in mM) : 20 CsCl, 20 tetraethylammonium chloride, 82 glutamate, 3 ATP-Mg, 0.5 NaH2PO4, 3 Na2-creatine P04, 11 EGTA, 10 HEPES (pH 7.25, CsOH). The bath and pipette solutions used in L-type calcium current studies minimized current"rundown" over time. Barium has a greater conductance than calcium through the L-type calcium channel and was used as charge carrier in L-type calcium channel experiments to increase whole-cell current amplitude. No protein was present in bath solutions, so concentrations of test agents represent free or unbound test agent.

T-type calcium currents were elicited by repetitive 200ms voltage steps to-30 mV applied from a holding potential of-80 mV. The repetitive voltage steps were continuously applied at a frequency of 0.2 Hz throughout experiments. Effects of compounds were calculated by measuring inhibition of peak current elicited during voltage steps. Peak current was measured from the holding current at-80 mV and used to calculate per cent inhibition. L-type calcium currents were elicited by repetitive 200ms voltage steps to 30 mV applied from a holding potential of-50 mV.

The repetitive voltage steps were continuously applied at a frequency of 0.2 Hz throughout experiments. Effects of compounds were calculated by measuring inhibition of peak current recorded at 30 mV. Data were sampled at rates at least two times the low pass filter rate. The flow rate was kept constant throughout the experiments (-5 ml/min). All membrane currents were recorded at 25°C.

The following Examples illustrate embodiments of the present invention, and are not intended to limit the scope of the claims. Abbreviations employed herein are defined below.

Abbreviations CH3CN = acetonitrile DCC = dicyclohexylcarbodiimide DCE = dichloroethane DCM = dichloromethane

DMAP = 4-dimethylaminopyridine DIPEA or DIEA = N,N-diisopropylethylamine DME = 1,2-dimethoxyethane DMF = dimethyl formamide EDCI = 1-3-dimethylaminopropyl)-3-ethylcarbodiimide Et2O = diethyl ether HOBT = 1-hydroxybenzotriazole EtOAc = ethyl acetate HC1 = hydrochloric acid IPA = isopropyl alcohol KOH = potassium hydroxide K2CO3 = potassium carbonate LiAlH4 lithium aluminum hydride MeCN = acetonitrile MeOH = methanol MgS04 = magnesium sulfate NaH = sodium hydride NaOH = sodium hydroxide NMP = 1-methyl-2-pyrrolidinone SOC12 = thionyl chloride TEA = triethylamine THF = tetrahydrofuran bp = boiling point g = gram (s) mg = milligram (s) ml = milliliter lil = microliter 1 = liter mmol = millimole umol = micromole mol = mole mp = melting point RT = room temperature NMR (Nuclear Magnetic resonance was performed on a Brucker 400 spectrometer (s = singlet, d = doublet, t = triplet, dd = doublet of doublet, m = multiplet) Elementary analysis were carried on a Carlo-Erba Mod 106 elementary analyzer Compounds of the Examples are identified by the example and step in which they are prepared (for example,"1A"denotes the title compound of step A of

Example 1), or by the example only where the compound is the title compound of the example (for example, "4"denotes the title compound of Example 4).

Example 1 6-Methyl-3- {3-[methyl-(4-phenoxy-benzoyl)-amino]-propyl}-4-(3-nitro-phe nyl)- 2-oxo-1, 2,3, 4-tetrahydro-pvrimidine-5-carboxvlic acid isopropyl ester To N-methyl-3-chloropropylamine hydrochloride (2.88g, 20mmol) and Di-tert-butyl dicarbonate (4. 3g, 20mmol) in THF (100ml) was added triethylamine (5. 6ml, 40mmol) dropwise. The mixture was stirred at RT overnight. The solution was diluted with 4: 1 EtOAc: hexane, washed with water, brine, dried and concentrated to give 1A (4. 28g, 100%).

To a stirred solution of lA (1.45g, 7mmol) in acetone (70ml) was added sodium iodide (10.5g, 70mmol). The mixture was stirred at 50°C for 20h. The solution was cooled and diluted with CH2C12, filtered and concentrated. Purification by flash chromatography on silica gel (1: 9 EtOAc/hexane as the elutant) gave 1B as an oil (800mg, 38%).

1C

To a stirred solution of 2-methoxy-6-methyl-4- (3-nitro-phenyl)-1, 4-dihydro- pyrimidine-5-carboxylic acid isopropyl ester (synthesized by the method in the reference J of Med. Chem, 1990,33 (5), 1510) (3.6g, 1 lmmol) in DMF (lOml) at 0°C was added sodium hydride (480mg, 12mmol) in portions. To this mixture was added 1B (3.6g, 12mmol) in DMF (lml) and the solution was stirred at RT for 5h. The solution was diluted with EtOAc, washed with water, brine, dried and concentrated.

Purification by flash chromatography on silica gel (1: 4 EtOAc/hexane as the elutant) gave 1C as a oil (3.6g, 66%). A solution of 1C (3.6g, 7. lmmol) in THF (36ml) and MeOH (36ml) was treated wit HC1 (3N, 72ml) and stirred for 2. 5h at 45°C. The solution was cooled, neutralized with aqueous sodium bicarbonate to pH 8 and extracted with CH2C12, washed with brine, dried and concentrated to give 1D Example 1 To a stirred solution of 1D (19. 5mg, 0. 05mmol) in CH2C12 (1ml) was added 4- phenyoxybenzoic acid (10. 7mg, 0. 05mmol) and 1, 3-Diisopropylcarbodiimide (11. 7, u1, 0.075mmol). The solution was stirred at RT overnight and then concentrated.

Purification by preparative HPLC gave the title compound as an oil. MS (M+H) 587, purity: 99. %.

The following compounds in Table 1 have been synthesized utilizing the procedures described in Example 1, utilizing the appropriate starting materials.

Table 1 Compound R7 A number Purity (%) M+H 2 \/ 3 oa 95 509 ) 4/==\. Y93585 93 > , _ 99 6 7 No 8 g, ) N 9 ? 10 0 ru-' ) 12 No2 , 13 \/ 14 F u-r' 15 , F No2 F \ 17 17 w 93 19 95 Con 20 2 \/ N02 w 2 = 23 0\ o q l o- 96 po 26 No2 28 ce , 89 w F 29 F F ru 31 N02 , 32 32 33 o , <-\/-u'' w 35 N02 /ou 36 NOz<539 No2 37 zon S--- 94 \, 39 , 40 / o-' ci ce 42 CF3 cl \/ ce , 44-- N°2 85 571 ici 46 razz , Qr , 95 49 o \/, , 50 N02 o N02 52 /Nz 99 53 IY NO2 .. \/ j 54 °'s k 55 /'v"' 98 56 ' ru

99 57 < i i wu 58 99 563 59 N r HPLC MassExample 60 4- (3-Chloro-phenyl)-6-methyl-3-(3-{methyl-[4-(2-phenoxy-ethoxy )-benzoyl]- amino} -propyl)-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid isopropyl ester 60A was prepared using the method described in 1C utilizing the appropriate starting materials.

60B was prepared using the method described in 1D utilizing the 60A.

Example 60 Example 60 was prepared from 60B using the method described for Example 1 to give the title compound. MS (M+H) 621, HPLCpurity, 99%.

The following compounds in Table 2 have been synthesized utilizing the procedures described in Example 60, utilizing the appropriate starting materials.

Table 2 Compound R 7 Mass numberPurity 61 592 OH 62 ci 63 cl3 64 582 0 65 93 588 66 ? 588 I I 67 o 68 CH3 97 574 o 0 69 ? CH3 94 659 NAZI FI F F 70 CH3 528 71 96 556 r° 72 F 99 568 o 73 4° CH3 98 590 zizi CH3 99 576 o 75 98 576 w o 76 CH3 580 o 77 99 562 o 78 0 79"-CoaF 0 o 80 98 526 0 81/CH3 0 0 82 F 100 580 F 0 83 CH3 556 w w i 0 T 0 84 99 526 _ CH3 o 0 86 i . 87 97 564 (3 0 88 94 558 r 0

89 0 zozo I Separation of Enantiomeric Intermediates Enantiomers A and B 60A was subjected to chiral separation using chiral prep HPLC (Chiralpak AD 5cmX50cm 2µm) using 5% IPA/hexane as elutant). The enantiomer coming out first from the prep column was named Enantiomer A and the later was named Enantiomer B The following compounds in Table 3 have been synthesized utilizing the procedures described in Example 60, substituting Enantiomer A for 60A.

Table 3 Compound R7 Mass number Purity M+H (%) 90/4 92 514 p 0) 11- 91 95 565 N O 92 ,, 93 o 94 r-° 95 97 618 N No 96 O 100 629 zu 0 97 / T° 98 s 99 100 99 100

101 r 102 \/N, N The following compounds in Table 4 have been synthesized utilizing the procedures described in Example 60, substituting Enantiomer B for 60A.

Table 4 Compound R7 Mass number Purity M+H (%) 103 p 514 104 N rye 105 X 106 612 I zu F 107 zozo

08 100 618 N'o N_ 109 o 100 629 zu i (3 110 594 \ rj° 111 100 588 X 112 113 114 0 \ Example 115 6-Methyl-4- (3-nitro-phenyl)-2-oxo-3-[3-(2-oxo-3-phenyl-imidazolidin-1-y l)- propyl]-1,2, 3, 4-tetrahydro-pyrimidine-5-carboxylic acid isopropyl ester 115A

To 2-metlioxy-6-methyl-4- (3-nitrophenyl)-1, 4-dehydropyrimidine-5-carboxylic acid isopropyl ester (3.7g, 11. 12mmol) in DMF (15ml) was added sodium hydride (60% dispersion in mineral oil, 320mg, 13. 3mmol). The mixture was stirred at RT for 15min followed by addition of 1,3-diiodopropane (5. 1ml, 44. 5mmol). The solution was stirred at RT for 2.7h and was diluted with EtOAc, washed with water, brine, dried and concentrated. Purification by flash chromatography on silica gel (1: 5 EtOAc/hexane as the elutant) gave 115A as an oil (l. lg, 85%).

115B To l-Phenyl-imidazolidin-2-one (39mg, 0.24mmol) in DMF (0. 5ml) was added sodium hydride (60% dispersion in mineral oil, 6mg, 0. 25mmol) followed by 115A (100mg, 0.2mmol). The solution was quenched with water, extracted with EtOAc, washed with water, brine, dried and concentrated. Purification by flash chromatography on silica gel (2: 3 EtOAc/hexane as the elutant) gave 115B as an oil (61mg, 60%).

Example 115 A solution of 115B in MeOH (lml) and THF (lml) was treated with 2N HC1 (3ml) and stirred for 2h at 45°C and then concentrated. The residue was purified by preparative HPLC to give the title compound as a light yellow solid (40mg). MS (M+H) 522, HPLC purity, 96%.

The following compounds in Table 5 have been synthesized utilizing the procedures described in Example 115, utilizing the appropriate starting materials.

Table 5

Compound A Mass number Purity 116 0 ly _. 117 117 zon J -N -Nt \/ Ni- 119 -) L J l N 120 NO Zizi r N/\N zon p - N N. 123 /2 123 -N 124 -N '/==\.-Y100'6 (T Enantiomer

125 \\ 99 566 NIN-/o NX__j Enantiomer B 126 ß 97 504 127 96 ",, 128 r\fV, /\N -- 129 NA nCH3 aï >95 567 3C cl3 c3 Enantiomer B 130/A L--/N \/ cl3 HIC HIC Enantiomer B 3 N/ w Enantiomer B RPLCExample 132 (BMS-587786) 4- (3-Chloro-phenyl)-3-{3-[3-(4-fluoro-phenyl)-1-methyl.-ureido ]-propyl}-6- methyl-2-oxo-1, 2,3,4-tetrahydro-pyridimidine-5-carboxylic acid isopropyl ester

To a solution of the 60B (0. 07 mmol) in dichloromethane (2 ml) was added 4- flourophenyl isocyanate (0.077 mmol) and triethyl amine (0.077 mmol. ). The solution was stirred at RT overnight (-l 8 h). The solution was concentrated. The residue was redissolved in methanol (1.5 ml), and purified by preparative HPLC to afford the title compound. MS (M+H) 576, HPLC purity, 99%.

The following compounds in Table 6 have been synthesized utilizing the procedures described in Example 132, utilizing the appropriate starting materials.

Table 6 Compound R Mass number Purity M+H (%) 133 N02 97 510 134 ci w zu 135 0 136 95 591 i 0 X HPLCExample 137 <BR> <BR> 6-Methvl-3-f 3- (methvl-phenoxvcarbonvl-amino)-propyll-4- (3-nitro-phenvl)-2- oxo-1, 2, 3, 4-tetrahvdro-pyrimidine-5-carbogvlic acid isopropyl ester

To a solution of the 60B (0.07 mmol) in dichloromethane (2 ml) was added phenyl chloroformate (0.077 mmol) and triethyl amine (0.077 mmol. ). The solution was stirred at RT overnight (-18 h). The solution was concentrated. The residue was redissolved in methanol (1.5 ml), and purified by preparative HPLC to afford the title compound. MS (M+H) 511, HPLC purity, 95%.

The following compounds in Table 7 have been synthesized utilizing the procedures described in Example 137, utilizing the appropriate starting materials.

Table 7 Compound R7 HPLC Mass number Purity M+H (%) 138 g/NO2 91 567 S 139 < Cl 99 514 Enantiomer A 140 5/C1 99 514 Enantiomer B 141 43o Enantiomer

142 w Enantiomer B XExample 143 <BR> <BR> 3-f3- (Benzenesulfonyl-methvl-amino)-propvil-6-methvl-4- (3-nitro-phenyl)-2-oxo- 1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid isopropyl ester To a stirred solution of ID (0. 04mmol) in CH2C12 (2. 6ml) was added phenyl sulphonyl chloride (0.04mmol) and triethylamine (0. 07mmol). The solution was stirred at RT overnight and then concentrated. Purification by preparative HPLC gave the title compound. MS (M+H) 531, HPLC purity, 97%.

The following compounds in Table 8 have been synthesized utilizing the procedures described in Example 143, utilizing the appropriate starting materials.

Table 8 Compound R7 HPLC Mass number Purity M+H (%) 144 545 ru 45 100 537 s 146 545 147 148 r 149 100 549 F 150 100 549 F 151 < 557 !- 152 559 153 r-° 154 565 ci 155 100 . 156 573 rw- 157 98 575 /cool 158 COOH 575 COOL COOH 159 90 579 X 160 161 e 162 'nu N 163 100 F CI 164 587 / vN 165 dz 98 588 , 166 0 o o 167 96 589 w N 168 tu/100 591 o _ 169 F F F 170 F 599 F ZF

171 95 599 c 172 100 599 ci Cj 173 ci 100 599 o 174 100 175 176 Br 177 100 624 N N 178 635 ce 179 zoo N j' N 180 s / 181 ci voX3 95 623 -, r"

95Example83<BR> <BR> 6-(2-Amino-ethoxymethvl)-4-(2-chloro-Phenvl)-3-f3-l methyl-(3-phenvl- propionyl)-amino]-propyl}-2-oxo-1, 2, 3*4-tetrahydro-pyrimidine-5-carboxYlic acid ethyl ester A mixture of 2-chloroethanol (10.00 g, 124.21 mmol), sodium azide (12.11 g, 186. 28 mmol) and tetrabutylammonium bromide (1.00 g, 3.10 mmol) was heated to 110°C and maintained at this temperature for 15 h under N2. The white slurry was cooled to RT and stirred in Et20 (50 mL). The white solid was filtered off and washed with some more Et20 (20 mL). The filtrate was concentrated in vacuo to afford 10.75 g of crude product as a yellow oil. The crude product was purified by chromatography using the ISCO Combiflash SQ16x (120 g Redisep silica gel column, 0 to 20% EtOAc in hexanes for 30 min at 40 mL/min) to afford 9.985 g (92%) of purified product (2 azido-ethanol) as a colorless oil.

1H NMR (500mHz, CDC13, 5) 3.785 (q, 2H, J = 5.3 Hz), 3.44 (t, 2H, J = 5.0 Hz), 1. 87 (t, 1H, J = 5.7 Hz) 183A: 4- (2-Azido-ethoxy)-3-oxo-butyric acid ethyl ester To a slurry of sodium hydride (0.80 g, 60% dispersion, 20 mmol) in anhydrous THF (10 mL) cooled to-30°C with a dry ice-acetone bath under N2 was slowly added a solution of 4-chloroacetoacetate (3.25 g, 19.75 mmol) in anhydrous THF (10 mL).

The mixture was kept cooled at-30°C and stirred for 30 min. This solution was transferred by cannula to another flask containing a slurry of sodium hydride (0.80 g, 60% dispersion, 20 mmol) and 2-azido-ethanol (1.72 g, 19.8 mmol) in anhydrous

THF (30 mL). After the addition, the temperature was allowed to warm up to RT and stirred overnight (ca. 15h). The mixture was acidified with IN HC1 and then extracted with EtOAc (100 mL). The EtOAc extract was washed with brine (50 mL), dried (Na2S04), filtered and concentrated in vacuo to afford 4.792 g of crude product as a brown oil. The crude product was purified by chromatography using the ISCO Combiflash SQ16x (120 g Redisep silica gel column, 0 to 70% EtOAc in hexanes for 30 min at 40 mL/min) to afford 2.932 g of purified material as a yellow oil.

IHNMR (500mHz, CDC13, o) 4.19 (s, 2H), 4.21-4. 17 (m, 2H), 3.69 (t, 2H, J = 5.0 Hz), 3.54 (s, 2H), 3.42 (t, 2H, J = 5 Hz), 1.27 (t, 3H, J = 7.1 Hz) 183B: 2- [2- (2-azido-ethoxy)-acetyl]-3- (2-chloro-phenyl)-acrylic acid ethyl ester A mixture of 4-(2-azido-ethoxy)-3-oxo-butyric acid ethyl ester (3 g, 13.94 mmol), 2- chlorobenzaldehyde (3 g, 21. 34 mmol) and pyridine (1.5 mL, 1.47 g, 18. 55 mmol) in EtOH (14 mL) was heated to 60°C and maintained at this temperature for 3h. The mixture was concentrated in vacuo. The concentrate was taken up in EtOAc (100 mL), washed successively with 1N HC1 (25 mL) and brine (25 mL), dried (Na2SO4), filtered, concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16x (120 gram Redisep silica gel column, 0 to 60% EtOAc in hexanes for 30 min at 40 mL/min) to afford 2.00 g of 2- [2- (2-azido- ethoxy)-acetyl]-3- (2-chloro-phenyl)-acrylic acid ethyl ester (mixture of E/Z isomers) and 1.01 g of recovered starting material.

183C : 4- (2-Azido-ethoxymethyl)-6- (2-chloro-phenyl)-2-methoxy-1, 6-dihydro- pyrimidine-5-carboxylic acid ethyl ester

A mixture of 2- [2- (2-azido-ethoxy)-acetyl]-3- (2-chloro-phenyl)-acrylic acid ethyl ester (1.50 g, 4.44 mmol), O-methylisourea sulfate (0.82 g, 6.66 mmol) and sodium bicarbonate (1.5 g, 17. 86 mmol) in N, N dimethylacetamide (25 mL) was heated to 80°C and maintained at this temperature overnight (ca. 15 h). The mixture was cooled to RT and then taken up in EtOAc (100 mL) and H20 (50 mL). The EtOAc extract was washed with brine (50 mL), dried (Na2S04), filtered, concentrated and dried in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16x (120 g Redisep silica gel column, 0 to 60% EtOAc in hexanes for 30 min at 40 mL/min) to afford 1.189 g (68% for 2 steps) of white solid as a purified product.

1H NMR (500mHz, CDC13, 8) 7.33-7. 29 (m, 2H), 7.21-7. 13 (m, 2H), 6.04 (s, 1H), 4.875 (d, 1H, J = 16. 7 Hz), 4.80 (d, 1H, J = 15.8 Hz), 3.96 (t, 2H, J = 7.0 Hz), 3.76- 3.73 (m, 2H), 3.67 (s, 3H), 3.49 (t, 2H, J = 4.9 Hz), 1.06 (t, 3H, J = 7.1 Hz) LC-MS, ESI [M+H] + : 392.05, 394. 02 (100: 32) 183D: (3-Iodo-propyl)-methyl-carbamic acid tert-butyl ester or N-methyl- (3- iodo-propyl)-BOC-amine A mixture of N-methyl- (3-chloro-phenyl) amine hydrochloride (4 g, 27.70 mmol), di- tert-butyl dicarbonate (6.1 g, 27.95 mmol) in IN aqueous NaOH (60mL) and THF (60 mL) was stirred at RT overnight (ca. 15h). The mixture was taken up in EtOAc (150 mL) and then washed with brine (2 x 100 mL). The organic extract was dried

(Na2S04), filtered, concentrated and dried in vacuo to afford 5.3663 g of colorless oil as crude product. The crude product and sodium iodide (25 g) in acetone (100 mL) was heated to 60°C and maintained at this temperature for 4h. The mixture was cooled to ambient RT and the solvent was removed in vacuo. The residue was taken up in EtOAc (200 mL) and H20 (150 mL). The EtOAc extract was washed with brine (100 mL), dried (Na2SO4), filtered and concentrated in vacuo to afford 5.32 g of crude product. The crude product was purified by chromatography using the ISCO Combiflash SQ16x (120 g Redisep silica gel column, 0 to 20% EtOAc in hexanes for 30 min at 40 mL/min) to afford 3.5413 g (49%, 2 steps) of purified material as a yellow oil.

1H NMR (500mHz, CDC13, 8) 3.27 (t, 2H, J = 6. 6 Hz), 3.14 (t, 2H, J = 6.8 Hz), 2.85 (s, 3 H), 2.03 (broad s, 2H), 1.45 (s, 9H) 183E: 4- (2-Azido-ethogymethyl)-1- [3- (te t-butoxycarbonyl-methyl-amino)- propyl]-6- (2-chloro-phenyl)-2-methoxy-1, 6-dihydro-pyrimidine-5-carboxylic acid ethyl ester To a stirring slurry of 4- (2-azido-ethoxymethyl)-6- (2-chloro-phenyl)-2-methoxy-1, 6- dihydro-pyrimidine-5-carboxylic acid methyl ester (3.00 g, 7.62 mmol) and potassium carbonate (2.10 g, 15.19 mmol) in anyhdrous DMF (25 mL) was added a solution of (3-iodo-propyl) -methyl-carbamic acid tert-butyl ester (3.40 g, 11.37 mmol) in DMF (5 mL). The mixture was maintained at RT overnight (ca. 15h) under N2. The mixture was taken up in EtOAc (100 mL) and H20 (50 mL). The organic extract was washed with brine (50 mL), dried (Na2S04), filtered, concentrated and dried in vacuo to afford 5.8 g of thick yellow oil as crude product. Analytical HPLC analysis of the crude product showed a mixture of desired product and corresponding regioisomer (7: 3). The crude product was purified by chromatography using the ISCO Combiflash SQ16x (120 g Redisep silica gel, 0 to 20% EtOAc in CH2Cl2 for 30 min

at 40 mL/min) to afford 2.097 g (49%) of purified material and, 0.521 g mixture of desired product (73%) with regioisomer (27%) and 0.616 g of regioisomer. Chiral separation of the enantiomers was done using the Chiralcel-OD column using 5% isopropanol in hexanes to afford 0.953 g of isomer A and 0.939 g of Isomer B.

1H NMR (500mHz, CDCl3, 8) 7.52 (dd, 1H, J = 7. 7 Hz, 1.7 Hz), 7.275 (d, 1H, J = 7.7 Hz), 7.22 (d, 1H, J = 7. 7 Hz), 7.18 9d, 1H, J = 7. 2 Hz), 5.94 (s, 1H), 4.775 (d, 1H, J = 13.7 Hz), 4.675 (d, 1H, J = 13. 8 Hz), 4.02-3. 96 (m, 2H), 3.91 (s, 3H), 3. 83-3. 77 (m, 2H), 3.44 (t, 2H, J = 5. 2 Hz), 3.40-3. 41 (m, 1H), 3.21-3. 14 (m, 1H), 3.14-3. 00 (m, 2H), 3.78 (d, 2H, J = 9. 9 Hz), 1.78 (br s, 1H), 1.41 (s, 9H), 1.51 (br s, 1H), 1.10 (t, 3H, J = 7.1 Hz).

LC-MS, ESI [M+H] + : 565.27, 567.26 (100: 32) 183F: 6- (2-Azido-ethoxymethyl)-4- (2-chloro-phenyl)-3- (3-methylamino-propyl)- 2-oxo-1, 2,3, 4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester A solution of racemic 4- (2-azido-ethoxymethyl)-1- [3- (tef t-butoxycarbonyl-methyl- amino)-propyl]-6- (2-chloro-phenyl)-2-methoxy-1, 6-dihydro-pyrimidine-5-carboxylic acid ethyl ester (200 mg, 0.354 mmol) in CH2C12 (3 mL) and trifluoroacetic acid (1.5 mL) was stirred at RT under N2 to remove the BOC protecting group. After 2h, IN aqueous HCl (1 mL) and THF (3 mL) was added to the mixture. The mixture was left to stir overnight. The mixture was taken up in EtOAc (50 mL) and basicified with saturated NaHC03 solution. The organic extract was washed with brine (25 mL), dried (Na2S04), filtered, concentrated and dried in vacuo 150 mg (93% crude yield) of thick yellowish oil as crude product.

1H NMR (500mHz, CDC13, 5) 7. 68 (br s, 1H), 7.435 (dd, 1H, J = 7.2 Hz, 2.2 Hz), 7.345 (dd, 1H, J = 7.1 Hz), 7.30-7. 24 (m, 2H), 5.85 (s, 1H), 4.82 (s, 2H), 4.01 (q, 2 H, J = 7 Hz), 3.80-3. 75 (m, 2H), 3.52 (t, 2H, J = 4.9 Hz), 3.47 (t, 2H, J = 6. 35 Hz), 2.82-

2.69 9m, 2H), 2.62 (s, 3H), 2.05-21. 98 (m, 1H), 1.67-1. 57 (m, 1H), 1. 11 (t, 3H, J = 7 Hz).

LC-MS, ESI [M+H] + : 451. 18, 453.18 (100: 32) <BR> <BR> 183G : 6-(2-Azido-ethoxymethyl)-4-(2-chloro-phenyl)-3-{3-[methyl-(3 -phenyl- propionyl)-amino]-propyl}-2-oxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxylic acid ethyl ester To a solution of crude 6- (2-azido-ethoxymethyl)-4- (2-chloro-phenyl)-3- (3- methylamino-propyl) -2-oxo-1, 2,3, 4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester (40 mg, 0.89 mmol) in CH2C12 (2 mL) was added triethylamine (25 ul, 18 mg, 0.179 mmol) followed by a solution of hydrocinnamoyl chloride (25 mg, 0.148 mmol) in CH2CI2 (0.5 ml). After 3h, the mixture was taken up in EtOAc (50 mL) and then washed with H20 (25 mL) and brine (25 mL). The organic extract was dried (Na2S04), filtered, concentrated in vacuo. The crude product was purified by chromatography using the ISCO Combiflash SQ16x (35 g Redisep silica gel, 20 to 100% EtOAC in hexanes for 20 min, hold at 100% EtOAc for 15 min at 30 mL/min) to afford 27.6 mg (53%) of the purified material as a thick oil.

1H NMR (500mHz, CDC13, 8) Rotamers observed at 25°C : 7.45-7. 41 (m, 2H), 7.23- 7.26 (m, 2H), 7.24-7. 17 (m, 5H), 5.84, 5.82 (2s, 1H), 4.82-4. 74 (m, 2H), 4.00 (q, 2H, J = 7.2 Hz), 3.745 (q, 2H, J = 4.9 Hz), 3.56-3. 42 (m, 4H), 3.31-3. 09 (m, 1H), 3.03- 2.88 (m, 3H), 2.84, 2.82 (2s, 3H), 2.59-2. 49 (m, 2H), 1.91-1. 75 (m, 1H), 1.57-1. 47 (m, 1H), 1.13-1. 09 (m, 3H).

LC-MS, ESI [M+H] + : 583.21, 585. 21 (100: 32) 183H: 6-(2-Amino-ethoxymethyl)-4-(2-chloro-phenyl)-3-{3-[methyl-(3 -phenyl- propionyl)-amino]-propyl}-2-oxo-1, 2,3, 4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester

A solution of 6-(2-azido-ethoxymethyl)-4-(2-chloro-phenyl)-3-{3-[methyl-(3 -phenyl- propionyl)-amino]-propyl}-2-oxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (27 mg, 0.046 mmol) in EtOH (5 mL) was hydrogenated in the presence of 5% palladium on calcium carbonate poisoned with lead (10 mg). After 3 h, the catalyst was removed using a filter syringe. The filtrate was concentrated in vacuo to afford 29 mg of thick, colorless oil as crude product (87% pure by analytical HPLC).

The crude product was purified by preparative HPLC (from 30% B to 100% B for 10 min, Solvent A = 90% H20-10% MeOH-0. 1% TFA Solvent B = 10% MeOH-90% H20-0. 1% TFA, at 20 mL/min using column YMC ODS S5 20 x 100 mm). The desired fractions were combined and concentrated to remove most of the MeOH. The concentrate was taken up in EtOAc (50 mL) and basicified with saturated aqueous NaHC03 solution. The EtOAc extract was washed with brine, dried (Na2S04), filtered, concentrated and dried in vacuo to afford 14.5 mg (43%) of purified material as a thick, colorless oil.

'H NMR (500mHz, CDC13, 8) Rotamers observed at 25°C : 7.47-7. 42 (m, 1H), 7. 31- 7.16 (m, 9H), 5.84, 5.82 (2s, 1H), 4.82-4. 74 (m, 2H), 4.02-3. 97 (m, 2H), 3.65-3. 40 (m, 3H), 3.31-3. 09 (m, 1H), 3.01-2. 97 (m, 2H), 2. 94-2_88 (m, 3H), 2.84, 2. 82 (2s, 3H), 2.59-2. 49 (m, 2H), 2.25-1. 95 (br s, 3H), 1.91-1. 75 (m, 1H), 1.59-1. 48 (m, 1H), 1.12-1. 09 (m, 3H).

LC-MS, ESI [M+H] + : 557.25, 559.25 (100: 32).

The following compounds in Table 9 have been synthesized utilizing the procedures described in Example 183 utilizing the appropriate starting materials.

Table 9 Cmpd. R7 Mass No. Pur. M+H (%) 184 557 ci Enantiomer A 185 -y Et 99 557 ci i Enantiomer B Et ci 187 188 90 571 U c. u'\\ 9. o/"J [t Et 93 601 ci 189 ci 93 558 9 191 cl--c s o

192 _ zizi J'"T'CH3 100 641 o 194, ° Et 100 655 i o EXAMPLE 195 195A Tetrabutyl ammonium iodide (0.39 mmol) was added to a solution of N-Boc 4- bromomethyl piperidine (0. 58 mmol; prepared as described in Bioorganic and Medicinal Chemistry Letters, 9,2615, (1999) ) in dimethylformamide (1 ml) at ambient temperature for 20 minutes. In a second vessel, NaH (0.47 mmol) was added to a solution of 2-methoxy-6-methyl-4- (3-chloro-phenyl)-1, 4-dihydro- pyrimidine-5-carboxylic acid isopropyl ester (0.39 mmol) in dimethylformamide (1 ml) at ambient temperature and stirred for 20 minutes. The piperidine solution was then added to the dihydropyrimidine solution and stirred for approximately 2 hours.

The reaction was quenched by addition of water, diluted with ethyl acetate, and subsequently washed with water and brine solution. The acetate layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting material was purified via silica gel chromatography utilizing 20% ethyl acetate/hexanes eluent affording the corresponding N Boc piperidine dihydropyrimidine intermediate 195A in 29% yield.

195B vs I 10XNYNH N 0 HCI salt H 195A was dissolved in a minimum amount of 1: 1 tetrahydrofuran/methanol and treated with excess 6 N hydrochloric acid solution at ambient temperature for 2.5 hours. Solvent was removed i7z vacuo affording hydrochloric acid salt 194B.

EXAMPLE 195: Title Compound A portion of salt 195B (0.12 mmol) was dissolved in dichloro methane (0.5 ml) and treated with triethylamine (0.2 mmol) and 4-phenoxy phenyl acetyl chloride at ambient temperature and stirred overnight. The reaction was concentrated, dissolved in a minimum amount of methanol, and purified via preparative HPLC utilizing CIS reverse phase column and solvent gradient of 30% to 100% methanol/water/0.5% trifluoroacetic acid. This afforded the title compound in 48% yield. MS (M+H) 603, HPLC purity, 95%.

EXAMPLE 196 196A

To a solution of 4- (3-chlorophenyl)-6-methyl-2-oxo-1, 2,3, 4-tetrahydro-pyrimidine-5- carboxylic acid isopropyl ester (prepared by methods described in Tetrahedron Letters, 41, 9075-9078, 2000; 2.0 gm, 6.48 mmol) in anhydrous DMF (10.0 mL) was added CS2CO3 (2.11 gm, 6.48 mmol) at room temperature under nitrogen atmosphere.

The reaction mixture was stirred at room temperature for 30 mins followed by the addition of 3-bromomethyl-benzoic acid methyl ester (1.5 gm, 6.54 mmol) in neat.

The reaction was allowed to stir at 70 C for 4hrs. The reaction was diluted with water and extracted with ethyl acetate. The ethyl acetate layer was washed with water followed by brine, dried over MgS04 and concentrated to obtain crude product which is a mixture of mono and dialkylated. This mixture was separated by flash Si02 column (30% EtOAc/Hexanes) to obtain 600 mg of dialkylated and 1.3 gm of compound 196A as a white solid.

196B To a solution of compound 196A (1.3 gm, 2.84 inmol) in a mixture of MeOH (5.0 mL) and THF (5.0 mL) was added a solution of NaOH (170 mg, 4.25 mmol) in water (0.5 mL) at room temperature. The reaction mixture was stirred at room temperature for 6 hrs. It was concentrated and dissolved in water (10.0 mL). The pH of this solution was adjusted to 7.00 with IN aqueous HC1. It was extracted with ethyl acetate. The ethyl acetate layer was washed with by brine, dried over MgS04 and concentrated to obtain 1.3 gm of crude 196B product which was used as it is for further reaction.

Example 196: Title Compound To a solution of compound 193B (33 mg, 0.075 mmol) in anhydrous DMF (1.0 mL) was added HOBT (12.0 mg, 0.089 mmol) followed by the addition of EDAC (17.0 mg, 0. 089 mmol) at room temperature under nitrogen. The reaction mixture was stirred at room temperature for 15 mins followed by the addition of amine (12.0 mg, 0. 08 mmol) in neat at room temperature. The reaction mixture was allowed to stir at

room temperature over night. The reaction was diluted with water and then extracted with ethyl acetate. Ethyl acetate layer was washed with water followed by brine, dried over MgS04 and concentrated to obtain crude product as a gum. This crude product was purified by prep HPLC (gradient, 20 to 100% B over 25 mins; A = 90% H20, 10% MeOH, 0. 1% TFA; B = 10% H20,90% MeOH, 0. 1% TFA). The fractions containing pure compound were combined, concentrated by speed vac and then lyophilized to obtain 31. 0 mg of compound 196 as white lyophilate.

HPLC purity, 100% Mass Spec (M+H) + = 574 The following compounds in Table 10 have been synthesized utilizing procedures described in either Example 195 or 196 utilizing the appropriate starting materials.

Table 10 Cmpd. R No. (%) 197 zozo O Enantiomer B 198 CON 0 Enantiomer B 199 o 96 635 UN

200 0 100 600 I I U kA